Antibiotics containing borinic acid complexes and methods of use

A composition comprising:

• a) one or more physiologically acceptable carriers;
• and
• b) a compound or solvent adduct having a structure which is a member selected from:
• wherein B is boron, O is oxygen
• wherein R* and R** are each independently selected from substituted or unsubstituted alkyl (C1-C4), substituted or unsubstituted cycloalkyl (C3-C7), substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted heterocycle,
• and wherein A is CH,
• and wherein D is CH,
• and wherein E is a member selected from OH, alkoxy or 2-(morpholino)ethoxy, CO2H or CO2alkyl
• and wherein m=0-2,
• and wherein R9 is H,
• wherein B is boron, O is oxygen
• wherein R* and R** are the same and are members selected from substituted or unsubstituted alkyl (C1-C4), substituted or unsubstituted cycloalkyl (C3-C7), substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted heterocycle,
• and wherein A is CH, CR10 or N,
• and wherein D is N, CH, or CR12,
• and wherein E is OH, alkoxy or 2-(morpholino)ethoxy, CO2H or CO2alkyl
• and wherein m=0-2,
• wherein R12 is selected from (CH2)kOH (where k=1, 2 or 3), CH2NH2, CH2NH-alkyl, CH2N(alkyl)2, CO2H, CO2alkyl, CONH2, OH, alkoxy, aryloxy, SH, S-alkyl, S-aryl, SO2alkyl, SO2N(alkyl)2, SO2NHalkyl, SO2NH2, SO3H, SCF3, CN, halogen, CF3, NO2, NH2, 2*-amino, 3*-amino, NH2SO2 and CONH2,
• and wherein R9 and R10 are members independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, (CH2)nOH (n=1 to 3), CH2NH2, CH2NHalkyl, CH2N(alkyl)2, halogen, CHO, CH═NOH, CO2H, CO2-alkyl, S-alkyl, SO2-alkyl, S-aryl, SO2N(alkyl)2, SO2NHalkyl, SO2NH2, NH2, alkoxy, CF3, SCF3, NO2, SO3H and OH;
• wherein B is boron, O is oxygen
• wherein R* and R** are the same and are members selected from substituted or unsubstituted alkyl (C1-C4), substituted or unsubstituted cycloalkyl (C3-C7), substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted heterocycle,
• and wherein A is CH, CR10 or N,
• and wherein D is N, CH, or CR12,
• and wherein E is H, OH, alkoxy or 2-(morpholino)ethoxy, CO2H or CO2alkyl
• and wherein m=0-2,
• wherein R12 is selected from (CH2)kOH (where k=1, 2 or 3), CH2NH2, CH2NH-alkyl, CH2N(alkyl)2, CO2H, CO2alkyl, CONH2, OH, alkoxy, aryloxy, SH, S-alkyl, S-aryl, SO2alkyl, SO2N(alkyl)2, SO2NHalkyl, SO2NH2, SO3H, SCF3, CN, halogen, CF3, NO2, NH2, 2*-amino, 3*-amino, NH2SO2 and CONH2,
• and wherein R9 and R10 are members independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, (CH2)nOH (n=1 to 3), CH2NH2, CH2NHalkyl, CH2N(alkyl)2, halogen, CHO, CH═NOH, CO2H, CO2-alkyl, S-alkyl, SO2-alkyl, S-aryl, SO2N(alkyl)2, SO2NHalkyl, SO2NH2, NH2, alkoxy, CF3, SCF3, NO2, SO3H and OH,
• and wherein R*** is H or alkyl
• and salts or acylated prodrugs of said chemical compound having a structure of said Formula.